The Role of Surgical Resection of the Primary Tumor in Metastatic Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis Publisher Pubmed



Kardoust Parizi M^{1, 2} ; Singla N³ ; Roupret M⁴ ; Margulis V⁵ ; Matsukawa A^{1, 6} ; Tsuboi I^{1, 7} ; Schulz R^{1, 8} ; Karakiewicz PI⁹ ; Teoh JYC¹⁰ ; Soria F¹¹ ; Shariat SF^{1, 5, 11, 12, 13, 14, 15, 16}
Source: Current Opinion in Urology Published:2025

Abstract

Purpose of reviewTo evaluate the role of extirpative surgery for the primary tumor in metastatic upper tract urothelial carcinoma (mUTUC).Recent findingsThe PubMed, Web of Science, and Cochrane Library were searched on July 2024 to identify relevant studies according to the Preferred Reporting Items for Systematic Review (PRISMA) statement. Studies were eligible for analysis if they compared oncologic outcomes between mUTUC patients who underwent surgical resection of the primary tumor and patients who did not. Cancer-specific survival (CSS) and overall survival (OS) were assessed using multivariate logistic regression analyses. We identified 2686 reports, of which 11 articles comprising 12 833 records were selected for this systematic review. Eight and three studies used Surveillance Epidemiology and End Results (SEER) and National Cancer Database (NCDB) databases, respectively. Surgical resection of the primary tumor was significantly associated with better CSS and OS in patients with mUTUC. Among the 5353 mUTUC patients included in our meta-analysis, radical nephroureterectomy (RNU) was independently associated with better OS with a pooled hazard ratio (HR) of 0.62 [95% confidence interval (CI) 0.54-0.72, P-<-0.05]. Subgroup analyses of studies restricted to mUTUC patients with distant lymph node metastasis (n-=-1372) revealed RNU to be independently associated with better OS with pooled HR: 0.44 (95% CI 0.28-0.67, P-<-0.05) together with systemic chemotherapy, primary tumor site in the ureter, lower T stage, and no locoregional lymph node involvement.SummarySurgical resection of the primary tumor offers oncologic survival benefits in select patients with mUTUC. However, in the absence of data from prospective randomized studies, it is essential to evaluate each patient individually as part of a collaborative multidisciplinary shared decision working with the patient. © 2025 Wolters Kluwer Health, Inc. All rights reserved.